Cogent Biosciences, Inc. (COGT)
NMS – Real vaqt narxi. Valyuta: USD
34.53
+0.43 (1.26%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Find any stock by ticker or company name

NMS – Real vaqt narxi. Valyuta: USD
34.53
+0.43 (1.26%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Cogent Biosciences, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, genetik jihatdan aniqlangan kasalliklar uchun aniq terapiyalarni ishlab chiqishga qaratilgan. Uning yetakchi mahsuloti nomzodi bezuklastinib (CGT9486) ni o'z ichiga oladi, bu KIT retseptorining tirozin kinazidagi mutatsiyalarga, shu jumladan tizimli mastotsitozni keltirib chiqaradigan KIT D816V mutatsiyasiga, shuningdek, oshqozon-ichak stromal o'smalari bo'lgan bemorlarda uchraydigan KIT ekzon 17 dagi boshqa mutatsiyalarga qarshi qaratilgan 3-bosqichli klinik sinovdagi selektiv tirozin kinaza inhibitörü. Kompaniya shuningdek, hujjatlashtirilgan FGFR mutatsiyalari, shu jumladan ilg'or xolangiokarsinomasi bo'lgan bemorlar uchun 1-bosqichli klinik sinovda bo'lgan qaytariladigan va selektiv fibroblast o'sish omil retseptor 2 inhibitörü CGT4859 ni; qattiq o'smalar tizimli va CNS bilan bog'liq ko'rsatmalarda davolanadigan va kam ta'minlangan mutatsiyalarga qaratilgan yangi ErbB2 mutant dasturi CGT4255 ni; va yangi PI3Kα mutant-selektiv inhibitörü CGT6297 ni ishlab chiqadi. U bezuklastinibni tadqiq qilish, ishlab chiqish va tijoratlashtirish bo'yicha Plexxikon Inc. bilan litsenziyalash shartnomasiga ega. Cogent Biosciences, Inc.ning shtab-kvartirasi Uoltem, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jessica Sachs M.D. | Chief Medical Officer |
| Dr. John Edward Robinson Ph.D. | Chief Scientific Officer |
| Mr. Abb Hayden | Senior Vice President of Sales |
| Mr. Andrew R. Robbins M.B.A. | President, CEO & Director |
| Mr. Brad Barnett | Chief Technology Officer |
| Mr. Cole Pinnow | Chief Commercial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | 10-Q | cogt-20260331.htm |
| 2026-04-23 | DEFA14A | d114023ddefa14a.htm |
| 2026-02-17 | S-8 | d39919ds8.htm |
| 2026-02-17 | 8-K | cogt-20260217.htm |
| 2025-12-08 | 8-K | d81277d8k.htm |
| 2025-11-18 | 8-K | d888858d8k.htm |
| 2025-11-13 | 8-K | d46097d8k.htm |
| 2025-11-10 | 8-K | d54064d8k.htm |
| 2025-11-07 | S-3ASR | d85082ds3asr.htm |
| 2025-11-07 | 10-Q | cogt-20250930.htm |
| Mr. Evan D. Kearns J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. John L. Green C.A., CPA | CFO & Principal Accounting Officer |
| Ms. Christi Waarich | Senior Director of Investor Relations |
| Ms. Erin Schellhammer | Chief People Officer |